Cargando…
Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells
BACKGROUND: Tamoxifen resistance presents a huge clinical challenge for breast cancer patients. An understanding of the mechanisms of tamoxifen resistance can guide development of efficient therapies to prevent drug resistance. METHODS: We first tested whether peptidylarginine deiminase 2 (PAD2) may...
Autores principales: | Li, Fujun, Miao, Lixia, Xue, Teng, Qin, Hao, Mondal, Santanu, Thompson, Paul R., Coonrod, Scott A., Liu, Xiaoqiu, Zhang, Xuesen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785896/ https://www.ncbi.nlm.nih.gov/pubmed/31601253 http://dx.doi.org/10.1186/s13046-019-1404-8 |
Ejemplares similares
-
Potential Role for PAD2 in Gene Regulation in Breast Cancer Cells
por: Cherrington, Brian D., et al.
Publicado: (2012) -
Peptidylarginine deiminase 4 overexpression resensitizes MCF-7/ADR breast cancer cells to adriamycin via GSK3β/p53 activation
por: Zhou, Qianqian, et al.
Publicado: (2019) -
Peptidylarginine deiminase 1-catalyzed histone citrullination is essential for early embryo development
por: Zhang, Xiaoqian, et al.
Publicado: (2016) -
A FluoPol-ABPP PAD2 High-Throughput Screen Identifies
the First Calcium Site Inhibitor Targeting the PADs
por: Lewallen, Daniel M., et al.
Publicado: (2014) -
Applicability of Small-Molecule Inhibitors in the Study of Peptidyl Arginine Deiminase 2 (PAD2) and PAD4
por: Martín Monreal, María Teresa, et al.
Publicado: (2021)